Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dan, Zhang, Yanyang, Tang, Lin, Wang, Fuzhen, Ye, Ying, Ma, Chao, Zheng, Hui, Yu, Wenzhou, Cao, Lei, Song, Yifan, Reyimu, Abuduwaili, Zhang, Xiaoxiao, Wang, Haifeng, Nie, Yifei, Lu, Mingxia, Qi, Muge, Li, Jun, Wang, Ruolin, Yang, Kaichao, Wang, Changshuang, Rodewald, Lawrence Everett, Gao, Geroge Fu, An, Zhijie, Yin, Zundong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837442/
https://www.ncbi.nlm.nih.gov/pubmed/35186369
http://dx.doi.org/10.46234/ccdcw2022.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837442/
https://www.ncbi.nlm.nih.gov/pubmed/35186369
http://dx.doi.org/10.46234/ccdcw2022.009

Ejemplares similares